ING Groep NV Decreases Holdings in Edwards Lifesciences Corporation $EW

ING Groep NV trimmed its stake in Edwards Lifesciences Corporation (NYSE:EW) by 33.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 53,298 shares of the medical research company’s stock after selling 27,387 shares during the quarter. ING Groep NV’s holdings in Edwards Lifesciences were worth $4,145,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Rosenberg Matthew Hamilton purchased a new position in Edwards Lifesciences in the second quarter valued at approximately $28,000. True Wealth Design LLC increased its position in Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares during the last quarter. NewSquare Capital LLC raised its stake in shares of Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 134 shares during the period. Hantz Financial Services Inc. lifted its position in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after buying an additional 164 shares during the last quarter. Finally, Rakuten Securities Inc. lifted its position in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Down 3.7%

Shares of Edwards Lifesciences stock opened at $76.39 on Friday. The company’s 50-day moving average price is $83.55 and its 200-day moving average price is $81.10. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a market cap of $44.33 billion, a price-to-earnings ratio of 41.74, a PEG ratio of 3.03 and a beta of 0.94.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the prior year, the firm posted $0.59 EPS. Edwards Lifesciences’s revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,370,184.06. This trade represents a 16.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. The trade was a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 43,804 shares of company stock valued at $3,699,082. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. The Goldman Sachs Group reissued a “buy” rating and issued a $95.00 price objective (down previously from $108.00) on shares of Edwards Lifesciences in a report on Wednesday. Truist Financial set a $89.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday. Barclays reiterated an “overweight” rating and issued a $104.00 target price (up previously from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Finally, Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Analyst upgrades and reiterated buys lift longer‑term outlook — Wells Fargo raised its price target to $100 and moved to “overweight,” while BTIG and several other firms reiterated Buy ratings with ~$103 targets, supporting upside expectations. Article Title
• Positive Sentiment: Strong revenue growth and TAVR momentum highlighted on the earnings call — Management emphasized sustained Transcatheter Aortic Valve Replacement (TAVR) and other structural‑heart growth drivers; the company is leaning into growth after the quarter. Article Title
• Positive Sentiment: Options/contrarian take: some traders see the post‑earnings weakness as a buying opportunity — commentary suggests cleared uncertainty after results could support a tactical bullish trade. Article Title
• Neutral Sentiment: Mixed earnings print — Q4 revenue topped expectations and grew year‑over‑year, but EPS missed estimates. Revenue strength supports the growth narrative, while the EPS shortfall creates near‑term uncertainty. Article Title
• Neutral Sentiment: Sector context — Comparative coverage of healthcare earnings (AstraZeneca vs. Edwards vs. Zimmer Biomet) highlights macro/peer performance but is not specific to EW’s fundamentals. Article Title
• Negative Sentiment: Shareholder‑rights notice from Halper Sadeh LLC adds legal/uncertainty risk — a public call encouraging shareholders to contact the firm can prompt selling or increase perceived governance risk. Article Title

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.